Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 50

Results For "exclusive"

598 News Found

Brinton ties up with Scholl Wellness Company
News | March 03, 2022

Brinton ties up with Scholl Wellness Company

Brinton Pharmaceuticals enters exclusive sales and distribution rights of Scholl foot care products including Krack cream


Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology
Biotech | March 03, 2022

Avenge Bio announces peer-reviewed publication on preclinical proof of concept for LOCOcyte platform technology

Ovarian cancer is one of the most difficult cancers to treat. It is typically not detected until later stages, and about 70 percent of patients will have recurrence after an initial treatment, which is often fatal


AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006
Biotech | March 01, 2022

AstraZeneca and Neurimmune enter licencing agreement to develop and commercialise NI006

Under the terms of the agreement, the upfront payment from Alexion to Neurimmune is US $ 30m


Fortis, Shalimar Bagh opens Mother and Child Care wing
Hospitals | February 24, 2022

Fortis, Shalimar Bagh opens Mother and Child Care wing

The new wing will cater to all aspects of mother and child health by offering comprehensive, end to end services in radiology, diagnostics, obstetric surgeries and an exclusive gynaecology emergency section


Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation
News | February 19, 2022

Hetero’s molnupiravir Phase III studies show 65 % reduction in hospitalisation

Early viral clearance (negative RT-PCR) and significant clinical improvement were observed within five days of administering the antiviral drug. There were no fatalities reported during the study


ITM receives investment of EUR 25 mn from Grand Pharma
News | February 18, 2022

ITM receives investment of EUR 25 mn from Grand Pharma

Equity investment follows recent EUR 520 m licensing agreement providing Grand Pharma (GP) access to three of ITM’s targeted radionuclide therapeutic and diagnostic candidates for Greater China


Pebble engages MD Anderson to evaluate multi-cannabinoid formulations in ovarian cancer
Biotech | February 17, 2022

Pebble engages MD Anderson to evaluate multi-cannabinoid formulations in ovarian cancer

Despite advances over the past 20 years, ovarian cancer treatment requires better standard of care


Lantern Pharma collaborates with GCCRI for pediatric cancer
Biotech | February 16, 2022

Lantern Pharma collaborates with GCCRI for pediatric cancer

Dr. Peter Houghton will lead the research collaboration for GCCRI and is widely regarded as a leading expert in pediatric cancer research and in the development of novel approaches to treating childhood cancers


BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies
interviews | February 15, 2022

BDR plans to enter the regulated markets this year: Raheel Shah, Director, BDR Group of Companies

BDR Pharmaceuticals is a home-grown company with operations in India and overseas. It’s known for its formulations portfolio and has a presence in specialty medicines. The company has ambitious plans as it has ramped up capacity and looking to foray into regulated markets. Raheel Shah, Director, BDR Group of Companies shares his insights in an interview with Thomas C Thottathil, Editor, Indian Pharma Post


Glenmark to commercialize AstraZeneca’s asthma drug in Columbia
Biotech | February 14, 2022

Glenmark to commercialize AstraZeneca’s asthma drug in Columbia

AstraZeneca will hold the registration and manufacture Pulmicort Respules, while Glenmark will commercialize the product in Columbia